- NEWS FEATURE
- Correction 13 January 2023
The ‘breakthrough’ obesity drugs that have stunned researchers
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Nature 613, 16-18 (2023)
Updates & Corrections
Correction 13 January 2023: This article has been clarified to reflect the fact that Jens Juul Holst was one of several scientists to discover and characterize GLP-1, alongside Joel Habener and Daniel Drucker.
Weghuber, D. et al. N. Engl. J. Med. 387, 2245–2257 (2022).
Wilding, J. P. H. et al. N. Engl. J. Med. 384, 989–1002 (2021).
Davies, M. et al. Lancet 397, 971–984 (2021).
Zhang, Y. et al. Nature 372, 425–432 (1994).
Holst, J. J., Ørskov, C., Vagn Nielsen, O. & Schwartz, T. W. FEBS Lett. 211, 169–174 (1987).
Pi-Sunyer, X. et al. N. Engl. J. Med. 373, 11–22 (2015).
Jastreboff, A. M. et al. N. Engl. J. Med. 387, 205–216 (2022).
Miyawaki, K. et al. Nature Med. 8, 738–742 (2002).
Urva, S. et al. Lancet 400, 1869–1881 (2022).
Wilding, J. P. H. et al. Diabetes Obes. Metab. 24, 1553–1564 (2022).
Tomiyama, A., Hunger, J., Nguyen-Cuu, J. & Wells, C. Int. J. Obes. 40, 883–886 (2016).
Li, J. et al. PLoS ONE 16, e0253696 (2021).